{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:49:47Z","timestamp":1790743787736,"version":"4.1.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T00:00:00Z","timestamp":1718496000000},"content-version":"am","delay-in-days":320,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.rdc.2023.03.004","type":"journal-article","created":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T08:55:14Z","timestamp":1682672114000},"page":"545-561","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Treatment Approaches to Granulomatosis with Polyangiitis and Microscopic Polyangiitis"],"prefix":"10.1016","volume":"49","author":[{"given":"Alvise","family":"Berti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divi","family":"Cornec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anisha B.","family":"Dua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.rdc.2023.03.004_bib1","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/rheumatology\/keaa667","article-title":"Prevalence and risk factors of relapse in patients with ANCA-associated vasculitis receiving cyclophosphamide induction: a systematic review and meta-analysis of large observational studies","volume":"60","author":"He","year":"2021","journal-title":"Rheumatol Oxf Engl"},{"issue":"3","key":"10.1016\/j.rdc.2023.03.004_bib2","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/ard.2010.137778","article-title":"Long-term patient survival in ANCA-associated vasculitis","volume":"70","author":"Flossmann","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.rdc.2023.03.004_bib3","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1136\/ard.2008.101279","article-title":"Modification and validation of the Birmingham Vasculitis Activity Score (version 3)","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.rdc.2023.03.004_bib4","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/art.1780400222","article-title":"Development and initial validation of the vasculitis damage index for the standardized clinical assessment of damage in the systemic vasculitides","volume":"40","author":"Exley","year":"1997","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.rdc.2023.03.004_bib5","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1213277","article-title":"Efficacy of remission-induction regimens for ANCA-associated vasculitis","volume":"369","author":"Specks","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.rdc.2023.03.004_bib6","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1681\/ASN.2010050477","article-title":"Histopathologic classification of ANCA-associated glomerulonephritis","volume":"21","author":"Berden","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.rdc.2023.03.004_bib7","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.kint.2017.01.002","article-title":"A\u00a0proposal for standardized grading of chronic changes in native kidney biopsy specimens","volume":"91","author":"Sethi","year":"2017","journal-title":"Kidney Int"},{"issue":"8","key":"10.1016\/j.rdc.2023.03.004_bib8","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1136\/annrheumdis-2017-212713","article-title":"Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire","volume":"77","author":"Robson","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.rdc.2023.03.004_bib9","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/acr.24634","article-title":"2021 American college of rheumatology\/vasculitis foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Care Res"},{"issue":"4S","key":"10.1016\/j.rdc.2023.03.004_bib10","first-page":"S1-276","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.rdc.2023.03.004_bib11","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12882-019-1226-0","article-title":"Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated Vasculitis: a multi-center retrospective cohort study","volume":"20","author":"Chanouzas","year":"2019","journal-title":"BMC Nephrol"},{"issue":"10","key":"10.1016\/j.rdc.2023.03.004_bib12","doi-asserted-by":"crossref","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody\u2014associated vasculitisa randomized trial","volume":"150","author":"de Groot","year":"2009","journal-title":"Ann Intern Med"},{"issue":"26","key":"10.1016\/j.rdc.2023.03.004_bib13","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1056\/NEJMoa0802311","article-title":"Azathioprine or methotrexate maintenance for ANCA-associated vasculitis","volume":"359","author":"Pagnoux","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.rdc.2023.03.004_bib14","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/art.39011","article-title":"Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy","volume":"67","author":"Pagnoux","year":"2015","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"issue":"7","key":"10.1016\/j.rdc.2023.03.004_bib15","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1056\/NEJMoa1803537","article-title":"Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis","volume":"382","author":"Walsh","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.rdc.2023.03.004_bib16","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.rdc.2023.03.004_bib17","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1001\/jama.2021.6615","article-title":"Effect of reduced-dose vs high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: a randomized clinical trial","volume":"325","author":"Furuta","year":"2021","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.rdc.2023.03.004_bib18","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1136\/annrheumdis-2019-216863","article-title":"Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis","volume":"79","author":"Smith","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.rdc.2023.03.004_bib19","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1681\/ASN.2016111179","article-title":"Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis","volume":"28","author":"Jayne","year":"2017","journal-title":"J\u00a0Am Soc Nephrol JASN"},{"issue":"8","key":"10.1016\/j.rdc.2023.03.004_bib20","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/acr.20176","article-title":"Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis","volume":"62","author":"Walsh","year":"2010","journal-title":"Arthritis Care Res"},{"issue":"27","key":"10.1016\/j.rdc.2023.03.004_bib21","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1056\/NEJM197112302852701","article-title":"Effect of cyclophosphamide upon the immune response in Wegener\u2019s granulomatosis","volume":"285","author":"Fauci","year":"1971","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.rdc.2023.03.004_bib22","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa020286","article-title":"A\u00a0randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies","volume":"349","author":"Jayne","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.rdc.2023.03.004_bib23","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/annrheumdis-2011-200477","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up","volume":"71","author":"Harper","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.rdc.2023.03.004_bib24","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1002\/art.21142","article-title":"Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody\u2013associated vasculitis","volume":"52","author":"De Groot","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.rdc.2023.03.004_bib25","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1002\/art.34547","article-title":"Brief Report: long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis","volume":"64","author":"Faurschou","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.rdc.2023.03.004_bib26","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1136\/annrheumdis-2018-214245","article-title":"Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial","volume":"78","author":"Jones","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.rdc.2023.03.004_bib27","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1093\/ndt\/gfab357","article-title":"Induction and maintenance of remission with mycophenolate mofetil in ANCA-associated vasculitis: a systematic review and meta-analysis","volume":"37","author":"Berti","year":"2022","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"10.1016\/j.rdc.2023.03.004_bib28","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1172\/JCI0215918","article-title":"Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice","volume":"110","author":"Xiao","year":"2002","journal-title":"J\u00a0Clin Invest"},{"issue":"12","key":"10.1016\/j.rdc.2023.03.004_bib29","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1002\/1529-0131(200112)44:12<2836::AID-ART471>3.0.CO;2-W","article-title":"Response of Wegener\u2019s granulomatosis to anti-CD20 chimeric monoclonal antibody therapy","volume":"44","author":"Specks","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.rdc.2023.03.004_bib30","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/art.20718","article-title":"Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis","volume":"52","author":"Keogh","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.rdc.2023.03.004_bib31","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.rdc.2023.03.004_bib32","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.rdc.2023.03.004_bib33","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1136\/annrheumdis-2015-208073","article-title":"Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type","volume":"75","author":"Unizony","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"19","key":"10.1016\/j.rdc.2023.03.004_bib34","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.rdc.2023.03.004_bib35","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/annrheumdis-2017-212878","article-title":"Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)","volume":"77","author":"Charles","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.rdc.2023.03.004_bib36","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/M19-3827","article-title":"Long-term rituximab use to maintain remission of antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial","volume":"173","author":"Charles","year":"2020","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1016\/j.rdc.2023.03.004_bib37","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/rheumatology\/kew199","article-title":"Ofatumumab for B cell depletion therapy in ANCA-associated vasculitis: a single-centre case series","volume":"55","author":"McAdoo","year":"2016","journal-title":"Rheumatol Oxf Engl"},{"issue":"9","key":"10.1016\/j.rdc.2023.03.004_bib38","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1093\/rheumatology\/keab916","article-title":"Obinutuzumab as treatment for ANCA-associated vasculitis","volume":"61","author":"Amudala","year":"2022","journal-title":"Rheumatol Oxf Engl"},{"issue":"6","key":"10.1016\/j.rdc.2023.03.004_bib39","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/art.40802","article-title":"Efficacy and safety of belimumab and azathioprine for maintenance of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled study","volume":"71","author":"Jayne","year":"2019","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"issue":"10320","key":"10.1016\/j.rdc.2023.03.004_bib40","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(21)02251-0","article-title":"Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sj\u00f6gren\u2019s syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial","volume":"399","author":"Bowman","year":"2022","journal-title":"Lancet Lond Engl"},{"issue":"6","key":"10.1016\/j.rdc.2023.03.004_bib41","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-Targeted CAR T\u00a0cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.rdc.2023.03.004_bib42","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.rdc.2023.03.004_bib43","first-page":"921","article-title":"Anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and vasculitis","volume":"135","author":"Jennette","year":"1989","journal-title":"Am J Pathol"},{"issue":"2","key":"10.1016\/j.rdc.2023.03.004_bib44","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1681\/ASN.2013101043","article-title":"With complements from ANCA mice","volume":"25","author":"Kettritz","year":"2014","journal-title":"J\u00a0Am Soc Nephrol JASN"},{"issue":"1","key":"10.1016\/j.rdc.2023.03.004_bib45","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2353\/ajpath.2007.060573","article-title":"Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies","volume":"170","author":"Xiao","year":"2007","journal-title":"Am J Pathol"},{"issue":"2","key":"10.1016\/j.rdc.2023.03.004_bib46","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1681\/ASN.2008050497","article-title":"C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis","volume":"20","author":"Schreiber","year":"2009","journal-title":"J\u00a0Am Soc Nephrol JASN"},{"issue":"3","key":"10.1016\/j.rdc.2023.03.004_bib47","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/cei.13515","article-title":"The rise of complement in ANCA-associated vasculitis: from marginal player to target of modern therapy","volume":"202","author":"Trivioli","year":"2020","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"10.1016\/j.rdc.2023.03.004_bib48","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/cei.13498","article-title":"The alternative complement pathway in ANCA-associated vasculitis: further evidence and a meta-analysis","volume":"202","author":"Moiseev","year":"2020","journal-title":"Clin Exp Immunol"},{"issue":"11","key":"10.1016\/j.rdc.2023.03.004_bib49","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/acr2.11185","article-title":"Adjunctive treatment with avacopan, an oral C5a receptor inhibitor, in patients with antineutrophil cytoplasmic antibody-associated vasculitis","volume":"2","author":"Merkel","year":"2020","journal-title":"ACR Open Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2023.03.004_bib50","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.nephro.2019.04.001","article-title":"Complement inhibition in ANCA vasculitis","volume":"15","author":"Jayne","year":"2019","journal-title":"Nephrol Ther"},{"issue":"7","key":"10.1016\/j.rdc.2023.03.004_bib51","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2007010090","article-title":"Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis","volume":"18","author":"Jayne","year":"2007","journal-title":"J\u00a0Am Soc Nephrol JASN"},{"key":"10.1016\/j.rdc.2023.03.004_bib52","doi-asserted-by":"crossref","first-page":"e064604","DOI":"10.1136\/bmj-2021-064604","article-title":"The effects of plasma exchange in patients with ANCA-associated vasculitis: an updated systematic review and meta-analysis","volume":"376","author":"Walsh","year":"2022","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.rdc.2023.03.004_bib53","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.kint.2017.03.014","article-title":"Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients","volume":"92","author":"McAdoo","year":"2017","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.rdc.2023.03.004_bib54","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13075-017-1321-1","article-title":"Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse","volume":"19","author":"Morgan","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"22","key":"10.1016\/j.rdc.2023.03.004_bib55","doi-asserted-by":"crossref","first-page":"e150999","DOI":"10.1172\/jci.insight.150999","article-title":"Circulating autoreactive proteinase 3+ B cells and tolerance checkpoints in ANCA-associated vasculitis","volume":"6","author":"Berti","year":"2021","journal-title":"JCI Insight"},{"issue":"3","key":"10.1016\/j.rdc.2023.03.004_bib56","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.41407","article-title":"New therapeutic targets in antineutrophil cytoplasm antibody-associated vasculitis","volume":"73","author":"Prendecki","year":"2021","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"issue":"1","key":"10.1016\/j.rdc.2023.03.004_bib57","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/bjh.15232","article-title":"A\u00a0tale of two antibodies: obinutuzumab versus rituximab","volume":"182","author":"Freeman","year":"2018","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.rdc.2023.03.004_bib58","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.semarthrit.2015.02.002","article-title":"Interleukin-6 in ANCA-associated vasculitis: Rationale for successful treatment with tocilizumab","volume":"45","author":"Berti","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.rdc.2023.03.004_bib59","doi-asserted-by":"crossref","first-page":"102302","DOI":"10.1016\/j.jaut.2019.07.001","article-title":"The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"105","author":"Berti","year":"2019","journal-title":"J\u00a0Autoimmun"},{"issue":"10","key":"10.1016\/j.rdc.2023.03.004_bib60","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1007\/s10067-017-3752-0","article-title":"Current clinical evidence of tocilizumab for the treatment of ANCA-associated vasculitis: a prospective case series for microscopic polyangiitis in a combination with corticosteroids and literature review","volume":"36","author":"Sakai","year":"2017","journal-title":"Clin Rheumatol"},{"issue":"7","key":"10.1016\/j.rdc.2023.03.004_bib61","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1136\/annrheumdis-2013-204164","article-title":"An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener\u2019s)","volume":"73","author":"Langford","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.rdc.2023.03.004_bib62","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/00005792-199601000-00003","article-title":"Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients","volume":"75","author":"Guillevin","year":"1996","journal-title":"Medicine (Baltim)"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X23000352?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X23000352?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:30:21Z","timestamp":1760182221000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X23000352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":62,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0889857X23000352"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2023.03.004","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment Approaches to Granulomatosis with Polyangiitis and Microscopic Polyangiitis","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2023.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}